• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Biotricity Inc.

    10/15/24 9:45:36 AM ET
    $BTCY
    Medical/Dental Instruments
    Health Care
    Get the next $BTCY alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-40761
    Issuer: BIOTRICITY INC.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 275 Shoreline Drive, Suite 150
    Redwood City CALIFORNIA 94065
    Telephone number: 416 587 8262
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2024-10-15 By Aravind Menon Hearings Advisor
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BTCY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BTCY

    DatePrice TargetRatingAnalyst
    11/20/2023Buy → Neutral
    H.C. Wainwright
    3/7/2022$5.00Buy
    Lake Street
    11/23/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BTCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Biotricity downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Biotricity from Buy to Neutral

      11/20/23 7:21:43 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Biotricity with a new price target

      Lake Street initiated coverage of Biotricity with a rating of Buy and set a new price target of $5.00

      3/7/22 9:01:18 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. initiated coverage on Biotricity with a new price target

      HC Wainwright & Co. initiated coverage of Biotricity with a rating of Buy and set a new price target of $6.00

      11/23/21 6:29:32 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

      FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

      7/17/25 9:33:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

      Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q

      7/15/25 5:05:00 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

      REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev

      4/8/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    SEC Filings

    See more
    • SEC Form 10-K filed by Biotricity Inc.

      10-K - BIOTRICITY INC. (0001630113) (Filer)

      7/15/25 5:27:01 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by Biotricity Inc.

      NT 10-K - BIOTRICITY INC. (0001630113) (Filer)

      6/30/25 9:20:12 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-Q/A filed by Biotricity Inc.

      10-Q/A - BIOTRICITY INC. (0001630113) (Filer)

      2/20/25 12:08:33 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Rosa David A

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/15/23 4:22:52 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Al-Siddiq Waqaas

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/14/23 4:26:54 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Ayanoglou John

      4 - BIOTRICITY INC. (0001630113) (Issuer)

      3/13/23 4:10:59 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Financials

    Live finance-specific insights

    See more
    • Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

      FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

      7/17/25 9:33:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

      Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025. The Company announces the best financial performance thus far and a shift to positive adjusted EBITDA. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q

      7/15/25 5:05:00 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

      REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025. This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges. Now in its sixth year, the Financial Times, in partnership with the research firm Statista, evaluated independent companies across the Americas based on disclosed rev

      4/8/25 8:15:00 AM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BTCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

      SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

      11/14/24 6:06:28 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Biotricity Inc.

      SC 13G - BIOTRICITY INC. (0001630113) (Subject)

      8/8/24 6:09:48 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care